Perspective: Assessing the Clinical Utility of Serum CTX in Postmenopausal Osteoporosis and Its Use in Predicting Risk of Osteonecrosis of the Jaw^†

• Pages: 561-574
• First Published: 04 December 2009

Inhibiting the Inhibitor: A New Route to Bone Anabolism^†

• Pages: 575-577
• First Published: 04 December 2009

Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis^†‡

• Pages: 578-588
• First Published: 04 December 2009

Experimental Folate and Vitamin B₁₂ Deficiency Does Not Alter Bone Quality in Rats^†

• Pages: 589-596
• First Published: 04 December 2009

Osteocyte Apoptosis Controls Activation of Intracortical Resorption in Response to Bone Fatigue^†

• Pages: 597-605
• First Published: 04 December 2009

Phenotypic Integration Among Trabecular and Cortical Bone Traits Establishes Mechanical Functionality of Inbred Mouse Vertebrae^†

• Pages: 606-620
• First Published: 04 December 2009

Mineralization and Bone Resorption Are Regulated by the Androgen Receptor in Male Mice^†

• Pages: 621-631
• First Published: 04 December 2009

Characterization of a Non-UBA Domain Missense Mutation of Sequestosome 1 (SQSTM1) in Paget's Disease of Bone^†

• Pages: 632-642
• First Published: 04 December 2009

Compound Heterozygous Mutations in the Vitamin D Receptor in a Patient With Hereditary 1,25-Dihydroxyvitamin D-Resistant Rickets With Alopecia^†

• Pages: 643-651
• First Published: 04 December 2009

FGF2 Stimulation of the Pyrophosphate-Generating Enzyme, PC-1, in Pre-Osteoblast Cells Is Mediated by RUNX2^†

• Pages: 652-662
• First Published: 04 December 2009

Maternal Dietary Patterns During Pregnancy and Childhood Bone Mass: A Longitudinal Study^†

• Pages: 663-668
• First Published: 04 December 2009

Large Osteoclasts in Pediatric Osteogenesis Imperfecta Patients Receiving Intravenous Pamidronate^†

• Pages: 669-674
• First Published: 04 December 2009

Estimates of the Proportion of Older White Women Who Would Be Recommended for Pharmacologic Treatment by the New U.S. National Osteoporosis Foundation Guidelines^†

• Pages: 675-680
• First Published: 04 December 2009

Interstate Variation in the Burden of Fragility Fractures^†

• Pages: 681-692
• First Published: 04 December 2009

Vitamin D Status, Parathyroid Function, Bone Turnover, and BMD in Postmenopausal Women With Osteoporosis: Global Perspective^†

• Pages: 693-701
• First Published: 04 December 2009

Diabetic Patients Have an Increased Risk of Vertebral Fractures Independent of BMD or Diabetic Complications^†

• Pages: 702-709
• First Published: 04 December 2009

Bivariate Genome-Wide Linkage Analysis of Femoral Bone Traits and Leg Lean Mass: Framingham Study^†

• Pages: 710-718
• First Published: 04 December 2009

Once-Weekly Risedronate in Men With Osteoporosis: Results of a 2-Year, Placebo-Controlled, Double-Blind, Multicenter Study^†

• Pages: 719-725
• First Published: 04 December 2009

Sequential Treatment of Severe Postmenopausal Osteoporosis After Teriparatide: Final Results of the Randomized, Controlled European Study of Forsteo (EUROFORS)^†‡

• Pages: 726-736
• First Published: 04 December 2009

Severity of Vertebral Fractures Is Associated With Alterations of Cortical Architecture in Postmenopausal Women^†

• Pages: 737-743
• First Published: 04 December 2009

Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study of ACE-011 (ActRIIA-IgG1) in Postmenopausal Women^†

• Pages: 744-752
• First Published: 04 December 2009

• Page: 753
• First Published: 04 December 2009

• Page: 754
• First Published: 04 December 2009

• Page: 755
• First Published: 04 December 2009

• Page: 756
• First Published: 04 December 2009

• Page: 758
• First Published: 04 December 2009